Blocking costimulatory pathways: Prospects for inducing transplantation tolerance

Immunotherapy

Volumn 2, Issue 4, 2010, Pages 497-509

  Verbinnen, Bert ^a   Van Gool, Stefaan W ^a   Ceuppens, Jan L ^b  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b NONE

Author keywords

antigen presenting cell; bone marrow transplantation; CD28; CD40; CD80; CD86; dendritic cell; graft versus host; inducible costimulator; solid organ transplantation

Indexed keywords

ABATACEPT; ALLOANTIGEN; B7 ANTIGEN; BASILIXIMAB; BELATACEPT; CD103 ANTIGEN; CD134 ANTIGEN; CD28 ANTIGEN; CD39 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD40 LIGAND MONOCLONAL ANTIBODY; CD86 ANTIGEN; COLECALCIFEROL; CORTICOSTEROID; CYCLOSPORIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DEXAMETHASONE; GLUCOCORTICOID INDUCED TUMOR NECROSIS FACTOR RECEPTOR; IMMUNOGLOBULIN G; INTERLEUKIN 10; L SELECTIN; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OX40 LIGAND; STEROID; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR FOXP3; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

ANTIGEN PRESENTING CELL; BINDING AFFINITY; BLOCKING FACTOR; CD25+ T LYMPHOCYTE; CD4+ CD25+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CHIMERA; CLONAL ANERGY; CORTICOSTEROID THERAPY; DISEASE MARKER; DONOR SPLENOCYTE TRANSFUSION; DOWN REGULATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GRAFT REJECTION; GRAFT SURVIVAL; GRAFT VERSUS HOST REACTION; HEART GRAFT; HUMAN; IMMUNE RESPONSE; IMMUNE SYSTEM; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; KIDNEY GRAFT; LIGAND BINDING; LYMPHOCYTE DIFFERENTIATION; LYMPHOCYTE PROLIFERATION; LYMPHOCYTE TRANSFUSION; MAJOR HISTOCOMPATIBILITY COMPLEX; PANCREAS ISLET TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; SKIN GRAFT; STEROID THERAPY; SURVIVAL TIME; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TRANSPLANTATION TOLERANCE; TREATMENT DURATION;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; LYMPHOCYTE ACTIVATION; MICE; SIGNAL TRANSDUCTION; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE;

EID: 77954995674     PISSN: 1750743X     EISSN: None     Source Type: Journal    
DOI: 10.2217/imt.10.31     Document Type: Review

References (105)

1. Starr TK, Jameson SC, Hogquist KA: Positive and negative selection of T cells. Annu. Rev. Immunol. 21, 139-176 (2003).
2. Alam SM, Travers PJ, Wung JL et al.: T-cell-receptor affinity and thymocyte positive selection. Nature 381(6583), 616-620 (1996).
3. Kappler JW, Roehm N, Marrack P: T cell tolerance by clonal elimination in the thymus. Cell 49(2), 273-280 (1987).
4. Redmond WL, Sherman LA: Peripheral tolerance of CD8 T lymphocytes. Immunity 22(3), 275-284 (2005).
5. Romagnani S: Regulation of the T cell response. Clin. Exp. Allergy 36(11), 1357-1366 (2006).
6. Schwartz RH: T cell anergy. Annu. Rev. Immunol. 21, 305-334 (2003).
7. Lamb JR, Skidmore BJ, Green N, Chiller JM, Feldmann M: Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J. Exp. Med. 157(5), 1434-1447 (1983).
8. Quill H, Schwartz RH: Stimulation of normal inducer T cell clones with antigen presented by purified Ia molecules in planar lipid membranes: specific induction of a long-lived state of proliferative nonresponsiveness. J. Immunol. 138(11), 3704-3712 (1987).
9. Frauwirth KA, Thompson CB: Activation and inhibition of lymphocytes by costimulation. J. Clin. Invest. 109(3), 295-299 (2002).
10. Powell JD: The induction and maintenance of T cell anergy. Clin. Immunol. 120(3), 239-246 (2006).
11. Greenwald RJ, Freeman GJ, Sharpe AH: The B7 family revisited. Annu. Rev. Immunol. 23, 515-548 (2005).
12. Sharpe AH, Freeman GJ: The B7-CD28 superfamily. Nat. Rev. Immunol. 2(2), 116-126 (2002).
13. Nurieva RI: Regulation of immune and autoimmune responses by ICOS-B7h interaction. Clin. Immunol. 115(1), 19-25 (2005).
14. Fife BT, Bluestone JA: Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways. Immunol. Rev. 224, 166-182 (2008).
15. Holmberg D, Cilio CM, Lundholm M, Motta V: CTLA-4 (CD152) and its involvement in autoimmune disease. Autoimmunity 38(3), 225-233 (2005).
16. Butte MJ, Keir ME, Phamduy TB, Sharpe AH, Freeman GJ: Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27(1), 111-122 (2007).
17. Croft M: Co-stimulatory members of the TNFR family: keys to effective T-cell immunity? Nat. Rev. Immunol. 3(8), 609-620 (2003).
18. Rocha B, Grandien A, Freitas AA: Anergy and exhaustion are independent mechanisms of peripheral T cell tolerance. J. Exp. Med. 181(3), 993-1003 (1995).
19. Zajac AJ, Blattman JN, Murali-Krishna K et al.: Viral immune evasion due to persistence of activated T cells without effector function. J. Exp. Med. 188(12), 2205-2213 (1998).
20. Singh NJ, Chen C, Schwartz RH: The impact of T cell intrinsic antigen adaptation on peripheral immune tolerance. PLoS Biol. 4(11), e340- (2006).
21. Kronenberg M, Rudensky A: Regulation of immunity by self-reactive T cells. Nature 435(7042), 598-604 (2005).
22. Sakaguchi S, Yamaguchi T, Nomura T, Ono M: Regulatory T cells and immune tolerance. Cell 133(5), 775-787 (2008).
23. Tang Q, Bluestone JA: The Foxp3+ regulatory T cell: a jack of all trades, master of regulation. Nat. Immunol. 9(3), 239-244 (2008).
24. Roncarolo MG, Gregori S, Battaglia M, Bacchetta R, Fleischhauer K, Levings MK: Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212, 28-50 (2006).
25. +) versus acquired Tr1 and Th3 regulatory T cells. Transplantation 77(1 Suppl.), S12-S15 (2004).
26. Sakaguchi S, Sakaguchi N, Asano M, Itoh M, Toda M: Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor a-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155(3), 1151-1164 (1995).
27. +CD25+ T cells inhibit both the induction and effector function of autoreactive T cells and represent a unique lineage of immunoregulatory cells. J. Immunol. 160(3), 1212-1218 (1998).
28. +CD25+ regulatory T cells. Nat. Immunol. 4(4), 330-336 (2003).
29. Hori S, Nomura T, Sakaguchi S: Control of regulatory T cell development by the transcription factor Foxp3. Science 299(5609), 1057-1061 (2003).
30. Brunkow ME, Jeffery EW, Hjerrild KA et al.: Disruption of a new forkhead/winged-helix protein, scurfin, results in the fatal lymphoproliferative disorder of the scurfy mouse. Nat. Genet. 27(1), 68-73 (2001).
31. Wildin RS, Ramsdell F, Peake J et al.: X-linked neonatal diabetes mellitus, enteropathy and endocrinopathy syndrome is the human equivalent of mouse scurfy. Nat. Genet. 27(1), 18-20 (2001).
32. Bennett CL, Christie J, Ramsdell F et al.: The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat. Genet. 27(1), 20-21 (2001).
33. Collison LW, Workman CJ, Kuo TT et al.: The inhibitory cytokine IL-35 contributes to regulatory T-cell function. Nature 450(7169), 566-569 (2007).
34. OGarra A, Vieira P: Regulatory T cells and mechanisms of immune system control. Nat. Med. 10(8), 801-805 (2004).
35. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389(6652), 737-742 (1997).
36. + T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)- and Th2-inducing cytokines. J. Exp. Med. 195(5), 603-616 (2002).
37. Steinbrink K, Wolfl M, Jonuleit H, Knop J, Enk AH: Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159(10), 4772-4780 (1997).
38. Sato K, Yamashita N, Baba M, Matsuyama T: Modified myeloid dendritic cells act as regulatory dendritic cells to induce anergic and regulatory T cells. Blood 101(9), 3581-3589 (2003).
39. Ito T, Yang M, Wang YH et al.: Plasmacytoid dendritic cells prime IL-10-producing T regulatory cells by inducible costimulator ligand. J. Exp. Med. 204(1), 105-115 (2007).
40. +. J. Exp. Med. 198(12), 1875-1886 (2003).
41. +. J. Immunol. 172(9), 5149-5153 (2004).
42. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV et al.: A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-β and retinoic acid-dependent mechanism. J. Exp. Med. 204(8), 1757-1764 (2007).
43. Linsley PS, Brady W, Urnes M, Grosmaire LS, Damle NK, Ledbetter JA: CTLA-4 is a second receptor for the B cell activation antigen B7. J. Exp. Med. 174(3), 561-569 (1991).
44. Lenschow DJ, Zeng Y, Thistlethwaite JR et al.: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA4lg. Science 257(5071), 789-792 (1992).
45. Turka LA, Linsley PS, Lin H et al.: T-cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc. Natl Acad. Sci. USA 89(22), 11102-11105 (1992).
46. Lin H, Bolling SF, Linsley PS et al.: Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion. J. Exp. Med. 178(5), 1801-1806 (1993).
47. Pearson TC, Alexander DZ, Winn KJ, Linsley PS, Lowry RP, Larsen CP: Transplantation tolerance induced by CTLA4-Ig. Transplantation 57(12), 1701-1706 (1994).
48. Cavinato RA, Casiraghi F, Azzollini N et al.: Pretransplant donor peripheral blood mononuclear cells infusion induces transplantation tolerance by generating regulatory T cells. Transplantation 79(9), 1034-1039 (2005).
49. Larsen CP, Elwood ET, Alexander DZ et al.: Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381(6581), 434-438 (1996).
50. Levisetti MG, Padrid PA, Szot GL et al.: Immunosuppressive effects of human CTLA4Ig in a non-human primate model of allogeneic pancreatic islet transplantation. J. Immunol. 159(11), 5187-5191 (1997).
51. Kirk AD, Harlan DM, Armstrong NN et al.: CTLA4-Ig and anti-CD40 ligand prevent renal allograft rejection in primates. Proc. Natl Acad. Sci. USA 94(16), 8789-8794 (1997).
52. Birsan T, Hausen B, Higgins JP et al.: Treatment with humanized monoclonal antibodies against CD80 and CD86 combined with sirolimus prolongs renal allograft survival in cynomolgus monkeys. Transplantation 75(12), 2106-2113 (2003).
53. Kirk AD, Tadaki DK, Celniker A et al.: Induction therapy with monoclonal antibodies specific for CD80 and CD86 delays the onset of acute renal allograft rejection in non-human primates. Transplantation 72(3), 377-384 (2001).
54. Larsen CP, Alexander DZ, Hollenbaugh D et al.: CD40-gp39 interactions play a critical role during allograft rejection. Suppression of allograft rejection by blockade of the CD40-gp39 pathway. Transplantation 61(1), 4-9 (1996).
55. Hancock WW, Sayegh MH, Zheng XG, Peach R, Linsley PS, Turka LA: Costimulatory function and expression of CD40 ligand, CD80, and CD86 in vascularized murine cardiac allograft rejection. Proc. Natl Acad. Sci. USA 93(24), 13967-13972 (1996).
56. + T cells, interferon-g, and CTLA4. J. Clin. Invest. 101(11), 2446-2455 (1998).
57. Larsen CP, Pearson TC: The CD40 pathway in allograft rejection, acceptance, and tolerance. Curr. Opin. Immunol. 9(5), 641-647 (1997).
58. Sebille F, Vanhove B, Soulillou JP: Mechanisms of tolerance induction: blockade of co-stimulation. Philos. Trans. R. Soc. Lond. B. Biol. Sci. 356(1409), 649-657 (2001).
59. Larsen CP, Pearson TC, Adams AB et al.: Rational development of LEA29Y (belatacept), a high-affinity variant of CTLA4-Ig with potent immunosuppressive properties. Am. J. Transplant. 5(3), 443-453 (2005).
60. Vincenti F, Larsen C, Durrbach A et al.: Costimulation blockade with belatacept in renal transplantation. N. Engl. J. Med. 353(8), 770-781 (2005).
61. Sidiropoulos PI, Boumpas DT: Lessons learned from anti-CD40L treatment in systemic lupus erythematosus patients. Lupus 13(5), 391-397 (2004).
62. Andre P, Prasad KS, Denis CV et al.: CD40L stabilizes arterial thrombi by a b3 integrin-dependent mechanism. Nat. Med. 8(3), 247-252 (2002).
63. Inwald DP, McDowall A, Peters MJ, Callard RE, Klein NJ: CD40 is constitutively expressed on platelets and provides a novel mechanism for platelet activation. Circ. Res. 92(9), 1041-1048 (2003).
64. Adams AB, Shirasugi N, Jones TR et al.: Development of a chimeric anti-CD40 monoclonal antibody that synergizes with LEA29Y to prolong islet allograft survival. J. Immunol. 174(1), 542-550 (2005).
65. Haanstra KG, Ringers J, Sick EA et al.: Prevention of kidney allograft rejection using anti-CD40 and anti-CD86 in primates. Transplantation 75(5), 637-643 (2003).
66. Harada H, Salama AD, Sho M et al.: The role of the ICOS-B7h T cell costimulatory pathway in transplantation immunity. J. Clin. Invest. 112(2), 234-243 (2003).
67. Kashizuka H, Sho M, Nomi T et al.: Role of the ICOS-B7h costimulatory pathway in the pathophysiology of chronic allograft rejection. Transplantation 79(9), 1045-1050 (2005).
68. Guillonneau C, Aubry V, Renaudin K et al.: Inhibition of chronic rejection and development of tolerogenic T cells after ICOS-ICOSL and CD40-CD40L co-stimulation blockade. Transplantation 80(4), 546-554 (2005).
69. Nabeyama K, Yasunami Y, Toyofuku A et al.: Beneficial effects of costimulatory blockade with anti-inducible costimulator antibody in conjunction with CTLA4Ig on prevention of islet xenograft rejection from rat to mouse. Transplantation 78(11), 1590-1596 (2004).
70. Zhang QW, Rabant M, Schenk A, Valujskikh A: ICOS-dependent and -independent functions of memory CD4 T cells in allograft rejection. Am. J. Transplant. 8(3), 497-506 (2008).
71. Curry AJ, Chikwe J, Smith XG et al.: OX40 (CD134) blockade inhibits the co-stimulatory cascade and promotes heart allograft survival. Transplantation 78(6), 807-814 (2004).
72. Demirci G, Amanullah F, Kewalaramani R et al.: Critical role of OX40 in CD28 and CD154-independent rejection. J. Immunol. 172(3), 1691-1698 (2004).
73. Yuan X, Salama AD, Dong V et al.: The role of the CD134-CD134 ligand costimulatory pathway in alloimmune responses in vivo. J. Immunol. 170(6), 2949-2955 (2003). (Pubitemid 36302166)
74. Van Gool SW, Vermeiren J, Rafiq K, Lorr K, De Boer M, Ceuppens JL: Blocking CD40 - CD154 and CD80/CD86 - CD28 during primary allogeneic stimulation results in T cell anergy and high IL-10 production. Eur. J. Immunol. 29(8), 2367-2375 (1999).
75. Vermeiren J, Ceuppens JL, Van GM et al.: Human T cell activation by costimulatory signal-deficient allogeneic cells induces inducible costimulator-expressing anergic T cells with regulatory cell activity. J. Immunol. 172(9), 5371-5378 (2004).
76. +CD25+ regulatory T cells. Transplantation 79(2), 147-156 (2005).
77. Wekerle T, Sayegh MH, Hill J et al.: Extrathymic T cell deletion and allogeneic stem cell engraftment induced with costimulatory blockade is followed by central T cell tolerance. J. Exp. Med. 187(12), 2037-2044 (1998).
78. Wells AD, Li XC, Li Y et al.: Requirement for T-cell apoptosis in the induction of peripheral transplantation tolerance. Nat. Med. 5(11), 1303-1307 (1999).
79. + cells. Am. J. Transplant. 1(4), 339-349 (2001).
80. Verbinnen B, Billiau AD, Vermeiren J et al.: Contribution of regulatory T cells and effector T cell deletion in tolerance induction by costimulation blockade. J. Immunol. 181(2), 1034-1042 (2008).
81. Bigenzahn S, Blaha P, Koporc Z et al.: The role of non-deletional tolerance mechanisms in a murine model of mixed chimerism with costimulation blockade. Am. J. Transplant. 5(6), 1237-1247 (2005).
82. Quezada SA, Bennett K, Blazar BR, Rudensky AY, Sakaguchi S, Noelle RJ: Analysis of the underlying cellular mechanisms of anti-CD154-induced graft tolerance: the interplay of clonal anergy and immune regulation. J. Immunol. 175(2), 771-779 (2005).
83. + regulatory T cells require CTLA-4 for the maintenance of systemic tolerance. J. Exp. Med. 206(2), 421-434 (2009).
84. Wing K, Onishi Y, Prieto-Martin P et al.: CTLA-4 control over Foxp3+ regulatory T cell function. Science 322(5899), 271-275 (2008).
85. Judge TA, Wu Z, Zheng XG, Sharpe AH, Sayegh MH, Turka LA: The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J. Immunol. 162(4), 1947-1951 (1999).
86. +-mediated responses under costimulation blockade. J. Immunol. 176(9), 5240-5246 (2006).
87. Tsai MK, Ho HN, Chien HF, Ou-Yang P, Lee CJ, Lee PH: The role of B7 ligands (CD80 and CD86) in CD152-mediated allograft tolerance: a crosscheck hypothesis. Transplantation 77(1), 48-54 (2004).
88. Poirier N, Azimzadeh AM, Zhang T et al.: Inducing CTLA-4-dependent immune regulation by selective CD28 blockade promotes regulatory T cells in organ transplantation. Sci. Transl. Med. 2(17), 17RA10 (2010).
89. Finger EB, Bluestone JA: When ligand becomes receptor - tolerance via B7 signaling on DCs. Nat. Immunol. 3(11), 1056-1057 (2002).
90. Puccetti P, Grohmann U: IDO and regulatory T cells: a role for reverse signalling and non-canonical NF-κB activation. Nat. Rev. Immunol. 7(10), 817-823 (2007).
91. Fallarino F, Grohmann U, Vacca C et al.: T cell apoptosis by tryptophan catabolism. Cell Death Differ. 9(10), 1069-1077 (2002).
92. Grohmann U, Orabona C, Fallarino F et al.: CTLA-4-Ig regulates tryptophan catabolism in vivo. Nat. Immunol. 3(11), 1097-1101 (2002).
93. Seveno C, Coulon F, Haspot F et al.: Induction of regulatory cells and control of cellular but not vascular rejection by costimulation blockade in hamster-to-rat heart xenotransplantation. Xenotransplantation 14(1), 25-33 (2007).
94. Pree I, Bigenzahn S, Fuchs D et al.: CTLA4Ig promotes the induction of hematopoietic chimerism and tolerance independently of Indoleamine-2,3- dioxygenase. Transplantation 83(5), 663-667 (2007).
95. Francisco LM, Salinas VH, Brown KE et al.: PD-L1 regulates the development, maintenance, and function of induced regulatory T cells. J. Exp. Med. 206(13), 3015-3029 (2009).
96. Chen M, Xiao X, Demirci G, Li XC: OX40 controls islet allograft tolerance in CD154 deficient mice by regulating FOXP3+ Tregs. Transplantation 85(11), 1659-1662 (2008).
97. Ito T, Wang YH, Duramad O et al.: OX40 ligand shuts down IL-10-producing regulatory T cells. Proc. Natl Acad. Sci. USA 103(35), 13138-13143 (2006).
98. Vu MD, Xiao X, Gao W et al.: OX40 costimulation turns off Foxp3+ Tregs. Blood 110(7), 2501-2510 (2007).
99. Wekerle T, Sykes M: Mixed chimerism and transplantation tolerance. Annu. Rev. Med. 52, 353-370 (2001).
100. Jacobsen N, Taaning E, Ladefoged J, Kristensen JK, Pedersen FK: Tolerance to an HLA-B,DR disparate kidney allograft after bone-marrow transplantation from same donor. Lancet 343(8900), 800 (1994).
101. Sorof JM, Koerper MA, Portale AA, Potter D, DeSantes K, Cowan M: Renal transplantation without chronic immunosuppression after T cell-depleted, HLA-mismatched bone marrow transplantation. Transplantation 59(11), 1633-1635 (1995).
102. Svendsen UG, Aggestrup S, Heilmann C et al.: Transplantation of a lobe of lung from mother to child following previous transplantation with maternal bone marrow. J. Heart Lung Transplant. 18(4), 388-390 (1999).
103. Wekerle T, Kurtz J, Ito H et al.: Allogeneic bone marrow transplantation with co-stimulatory blockade induces macrochimerism and tolerance without cytoreductive host treatment. Nat. Med. 6(4), 464-469 (2000).
104. Miller DM, Thornley TB, Pearson T et al.: TLR agonists prevent the establishment of allogeneic hematopoietic chimerism in mice treated with costimulation blockade. J. Immunol. 182(9), 5547-5559 (2009).
105. Seung E, Mordes JP, Rossini AA, Greiner DL: Hematopoietic chimerism and central tolerance created by peripheral-tolerance induction without myeloablative conditioning. J. Clin. Invest. 112(5), 795-808 (2003).